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บทคดัยอ่ 
วตัถปุระสงค:์ เพือ่ศกึษาอตัราการบรรลุเป้าหมายระดบัไขมนัในเลอืดชนิดแอลดี
แอล (LDL-C) ในผูป้่วยโรคหลอดเลอืดสมองแบบตบีที่มภีาวะไขมนัในเลอืดสูง 
ของสถาบนัประสาทวทิยา และการเกดิอาการไม่พงึประสงคแ์บบ myalgia และ 
rhabdomyolysis จากการใชย้ากลุ่มสเตตนิ วิธีการศึกษา: การศกึษาเชงิพรรณนา
แบบย้อนหลัง ศึกษาที่หอผู้ป่วยโรคหลอดเลือดสมอง  ในช่วงมีนาคมถึง
พฤศจกิายน พ.ศ. 2554 บนัทกึขอ้มลูและค่าระดบัไขมนัในเลอืดจากเวชระเบยีน
เมื่อผูป้่วยเขา้รบัการรกัษาในหอผูป้่วยและตดิตามค่าดงักล่าวอกีครัง้เมือ่ผูป้่วยมา
รบัการตดิตามรกัษาในช่วงเวลา 1 ปี ผลการศึกษา: ศกึษาผูป้่วยทัง้สิน้ 197 คนที่
เขา้รบัการรกัษาทีห่น่วยโรคหลอดเลอืดสมองตบี โดยแบ่งเป็น 4 กลุ่ม กลุ่มเอ (ไม่
เป็นโรคเบาหวานและไมเ่คยไดร้บัยาสเตตนิ)  กลุ่มบ ี(ไมเ่ป็นโรคเบาหวานและเคย
ไดร้บัยาสเตตนิ)  กลุ่มซ ี(เป็นโรคเบาหวานและไม่เคยไดร้บัยากลุ่มสเตตนิ) กลุ่มด ี
(เป็นโรคเบาหวานและเคยไดร้บัยาสเตตนิ) อตัราการบรรลุเป้าหมายระดบั LDL-C 
เป็น 82.22%, 68.89%, 21.74% และ 37.04% ในกลุ่มเอ, บ,ี ซ ีและดตีามลําดบั 
พบว่าใช ้simvastatin มากทีสุ่ด (89.34%) ขนาดยาอยู่ระหว่าง 10 – 40 มก./วนั 
ไม่พบอาการ myalgia และ rhabdomyolysis  สรปุ: ผูป้่วยโรคหลอดเลอืดสมอง
แบบตบีที่มภีาวะไขมนัในเลอืดสูงและมโีรคเบาหวานมอีตัราบรรลุเป้าหมายของ
ระดบั LDL-C ค่อนขา้งตํ่าเมื่อเทยีบกบักลุ่มทีไ่ม่มโีรคเบาหวาน ผูป้่วยส่วนใหญ่
ไดร้บัยาสเตตนิทีม่คีวามแรงตํ่า และไมพ่บอาการขา้งเคยีงจากยาสเตตนิ  
คาํสาํคญั: การบรรลุเป้าหมาย, โรคหลอดเลอืดสมองแบบตบี, ไขมนัชนิดแอลดี
แอล, สเตตนิ  
Abstract 
Objective: To determine the goal achievement rate of LDL-C in patients 
with ischemic stroke and hyperlipidemia at Prasat Neurological Institute 
(PNI) and incidence of adverse effects of statins namely myalgia and 
rhabdomyolysis. Method: With descriptive and retrospective design, 
patients with ischemic stroke and hyperlipidemia admitted in the stroke unit 
at PNI during March to September 2011 were studied by chart review. Lipid 
profile levels at admission and within 1 year after discharge were recorded. 
Results: A total of 197 patients admitted stroke unit during March to 
November 2011. Four groups of patients were classified: patients with no 
diabetes and no statin use (group A), no diabetes with statin use (group B), 
diabetes patients with no statin use (group C), and diabetes patients with 
statin use (group D). LDL-goal achievement rates were 82.22%, 68.89%, 
21.74%, and 37.04% in groups A, B, C and D, respectively. Simvastatin 
was the most prescribed lipid lowering agent (89.34%) with a dose range of 
10 to 40 mg per day.  No myalgia or rhabdomyolysis was found. 
Conclusions: Low rates of LDL-goal achievement were found in diabetic 
patients with ischemic stroke and hyperlipidemia. Most patients were on 
simvastatin and no adverse effects of statin were found.  
Keywords: goal achievement, ischemic stroke , LDL–C, statins  
 
Introduction
Hyperlipidemia is a healthcare problem in Thai 
population and one of the important risk factors in coronary 
heart disease, ischemic heart disease, acute myocardial 
infarction, peripheral arterial disease, and cerebrovascular 
disease. Stroke is a major cause of mortality and morbidity 
in Thailand. The data from the cause of death in 1990 
revealed that stroke was a major cause of death in female 
and a third of death in male Thai people.1 Moreover, this 
rate also increases every year in Thailand. Stroke is also a 
leading cause of functional impairments, with 20% of 
survivors requiring institutional care after 3 months and 15% 
to 30% being permanently disabled. Prevalence of stroke in 
Thailand is 690 : 100,000 population , approximately almost 
500,000 stroke patients per 72 millions of Thai people.2 
  
Large epidemiology studies in ischemic stroke have 
shown a modest association of elevated total cholesterol or 
low-density lipoprotein cholesterol (LDL-C) with the 
increased risk of ischemic stroke and the relationship 
between low LDL-C and the greater risk of intracerebral 
hemorrhage.3  
The use of 3-hydroxy-3-methyglutaryl coenzyme A 
reductase inhibitors (statins) has been approved by 
regulatory agencies for prevention of ischemic stroke in 
patients with coronary heart disease (CHD). Statins therapy 
with intensive lipid-lowering effects is recommended for 
patients with atherosclerotic ischemic stroke or transient 
ischemic attack (TIA) and without known CHD to reduce the 
risk of stroke and cardiovascular events. 4 For those patients 
with atherosclerotic ischemic stroke or TIA and history of 
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CHD, it is recommended that clinicians follow the current 
2011 the American Heart Association/American Stroke 
Association (AHA/ASA) guidelines5 for lipid management, 
which emphasize utilization of National Cholesterol 
Education Panel III guidelines (NCEP III).6 
Prasat Neurological Institute (PNI), an excellence center 
for the advancement in stroke research and treatment in 
Thailand, has been providing care for a total of 22,000 out-
patients and 1,000 in-patients with cerebrovascular diseases 
annually, based on data from 2008 to 2010. Multidisciplinary 
team and also clinical pharmacist have been working in the 
stroke unit since 2010. According to the concept of 
aggressive reduction in cholesterol level, we undertook 
retrospective charts review to determine the goal 
achievement of LDL-C levels in patients with ischemic stroke 
and hyperlipidemia and prevalence of adverse drug reactions 
including myalgia and rhabdomyolysis in these patients.  
  
Methods 
A cross-sectional descriptive design was employed in 
this study. The study was conducted at the inpatient 
department (IPD) of the Stroke Unit at Prasat Neurological 
Institute, Bangkok, Thailand, during March to November 
2011. This institution is under the Department of Medical 
Services, Ministry of Public Health, Thailand.  
Sample in this study was ischemic stroke patients with 
hyperlipidemia admitted in the Stroke Unit, Prasat 
Neurological Institute during March to November 2011. The 
inclusion criteria were as follows: patients who received 
statin drug before or during admission and their baseline 
LDL-C level were recorded before hospital discharge. The 
exclusion criteria included patients with diagnosis of 
cardioembolic stroke or loss of contact after hospital 
discharge. 
 
Data collection procedure 
Demographic data including age, gender, underlying 
diseases, drug allergy history, smoking and alcohol use 
history were obtained from medical chart. Data regarding 
general, medical and family history were recorded at the 
Stroke Unit during admission by patient interview and 
medical chart review. All related laboratory tests including 
lipid profiles, liver function tests (AST, ALT), creatine kinase, 
fasting blood sugar and HbA1C levels were obtained during 
admission. The first laboratory tests and any adverse drug 
reactions including myalgia and rhabdomyolysis within one 
year after discharge from the Stroke Unit were recorded by 
medical chart review. For these laboratory test and adverse 
drug reactions data to be eligible, the patients had to be 
taking the same statin dose as the one during admission. 
Patients were classified into 4 groups according to their 
diabetes mellitus (DM) diagnosis and statin use before 
admission; patients with no DM and no statin use before 
admission (group A), patients with no DM and with statin use 
before admission (group B), patients with DM and no statin 
use before admission (group C), and patients with DM and 
statin use before admission (group D). Their LDL goal 
achievements based on the follow-up measures were set 
according to their DM status: < 100 mg/dL for those with no 
DM (groups A and B) and < 70 mg/dL for those with DM 
(groups C and D).  
This study was approved by the Institutional Review 
Board and Independent Ethics Committee of the Prasat 
Neurological Institute (approval number: 2.205/2554; 
approval date: December 3, 2010).  
 
Data Analysis 
Descriptive statistics including frequency, percentage, 
range, mean, and standard deviation were used to describe 
demographic data, laboratory data at admission and follow 
up, mean LDL-C and goal achievement of LDL-C level. 
Paired t–test was used to compare means of laboratory data 
and LDL-C at admission with those at follow-up visit. 
  
Results 
A total number of 197 patients admitted to the Stroke 
Unit during March to November 2011 were enrolled in this 
study. Demographic data are presented in Table 1. There 
were slightly more male patients than female counterparts in 
most groups except in group D (patients with DM and statin 
use before admission). Their mean ages were comparable 
(60.54 to 63.32 years). The majority in each group never 
smoked and never drank of which the highest proportions of 
both habits were found in group D (78.95% and 84.21%, 
respectively). The highest proportions of present smoking 
(44.12%) and present drinking and 38.24%) were found in 
group A (no DM and no statin use before admission).  
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Table 1 Demographic data of 197 patients with ischemic stroke 
and hyperlipidemia.  
Demographic data 
Group 
A 
(N = 68) 
B 
(N = 59) 
C 
(N = 32) 
D 
(N = 38) 
Gender (%)     
Male 
Female  
47 (69.11%) 
21 (30.89%) 
33 (55.93%) 
26 (44.07)% 
17 (53.13%) 
15 (46.87%) 
14 (36.84%) 
24 (63.16%) 
Mean age (years) 60.54 63.32 62.59 62.89 
Standard deviation 
Range 
13.29 
16 - 85 
12.68 
35 - 83 
10.94 
44 - 85 
9.66 
43 - 78 
Smoking history (%)     
Never smoking  
Past smoking 
Present smoking 
Unknown 
35 (51.47%) 
3 (4.41%) 
30 (44.12%) 
0 (0.00%) 
39 (66.11%) 
1 (1.69%) 
18 (30.51%) 
1 (1.69%) 
14 (43.75%) 
5 (15.63%) 
13 (40.62%) 
0 (0.00%) 
30 (78.95%) 
1 (2.63%) 
7 (18.42%) 
0 (0.00%) 
Alcohol drinking (%)     
Never  
Past drinking  
Present drinking  
Unknown 
39 (57.35%) 
3 (4.41%) 
26 (38.24%) 
0 (0.00%) 
36 (61.02%) 
4 (6.78%) 
18 (30.51%) 
1 (1.69%) 
18 (56.25%) 
3 (9.38%) 
11 (34.37%) 
0 (0.00%) 
32 (84.21%) 
1 (2.63%) 
5 (13.16%) 
0 (0.00%) 
Note: Groups of patients: group A = patients with no diabetes mellitus (DM) and no statin use admission; group 
B = patients with no DM and with statin use admission; group C = patients with DM and no statin use admission; 
group D = patients with DM and statin use admission. 
Past smoking = smoking was discontinued more than 1 year.  
Past drinking = drinking was discontinued more than 1 year.  
 
Laboratory data at admission and follow-up are 
presented in Table 2. Total cholesterol levels decreased 
significantly from admission both in groups A (from 206.24 to 
147.61 mg/dL) and C (from 214.47 to 172.23 mg/dL) of 
which patients did not take any statin before admission (P < 
0.001 for both groups). As expected, total cholesterol levels 
at admission in groups B (170.20 mg/dL) and D (172.23 
mg/dL) where lower than those in groups A and C of which 
patients had not been any statins before admission.  
HDL levels increased significantly in all groups where the 
mean HDL levels at follow-up of more than 45 mg/dL were 
found in all groups. Triglyceride levels decreased slightly 
from admission with no statistical significance.  
Triglyceride levels decreased in all groups with no 
statistical significance. Patients in groups with statin use 
(groups B and D) had triglyceride levels at admission lower 
than their counterparts as expected.  
ALT levels increased from admission among patients 
who did not use statin before admission (from 22.52 to 27.73 
IU/L in group A and from 27.08 to 30.32 IU/L in group C), 
while those in patients who had been using statins 
decreased slightly (from 25.26 to 24.86 IU/L in group B and 
from 28.47 to 24.26 IU/L in group D). Changes in all 4 
groups, however, did not reach any statistical significance. In 
constrast to ALT, AST levels decreased in all 4 groups with 
a statistical significance found in group D (from 31.59 to 
23.37 IU/L, P = 0.014).  
Creatine kinase levels were obtained in a very small 
number of patients in all 4 groups. Even with an increased 
level at follow-up in each of the 4 groups, creatine kinase 
levels cannot be test for statistical significance.  
Fast blood sugar levels were found decreasing in all 
groups with no statistical significance. For HbA1c levels, a 
decrease in groups C and D (diabetes patients in both 
groups) was found with no statistical significance; while such 
changes with a very small magnitude were also found in 
patients with no diabetes (groups A and B) and could not be 
tested for statistical significance because a small number of 
patients were tested. As expected, patients with no diabetes 
(groups A and B) had fasting blood sugar and HbA1c levels 
lower than those of their counterparts. 
In terms of LDL (Table 2), LDLD levels at admission in 
patients with statin use (106.05 mg/dL in group B and 
113.37 mg/dL in group D) where higher than those in 
patients with no statin use (140.93 mg/dL in group A and 
141.38 mg/dL in group C). Decreases in LDL levels at 
follow-up were found with statistical significance in all groups 
(P < 0.001, = 0.01, < 0.001 and = 0.01, in groups A, B, C 
and D respectively). Largest decreases were found in groups 
A (from 140.93 to 85.18 mg/dL) and C (from 141.38 to 
100.43 mg/dL) of which the patients had not used any 
statins before admission.  
Regarding LDL-goal achievement based on follow-up 
measures (Table 3), patients in group A and B (no diabetes) 
were expected to have an LDL level of less than 100 mg/dL) 
while those in groups C and D were to have less than 70 
mg/dL. It was found that 82.22% and 68.89% of patients in 
groups A and B, respectively, and 21.74% and 37.04% of 
patients in groups C and D, respectively, achieved their 
respective LDL goals. 
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Table 2 Laboratory measures at admission and follow–up in 4 groups of patients.  
Laboratory measures 
Group A 
P- 
value* 
Group B 
P- 
value* 
Group C 
P- 
value* 
Group D 
P- 
value* at  
admission 
at  
follow-up 
at  
admission 
at  
follow-up 
at  
admission 
at  
follow-up 
at  
admission 
at  
follow-up 
Total cholesterol (mg/dL) 
Mean (SD)  206.24 (36.44) 147.61 (28.26) < 0.001 170.20 (44.48) 159.91 (28.27) 0.604 214.47 (52.31) 172.23 (32.83) < 0.001 174.33 (52.20) 161.71 (59.71) 0.148 
Range 119 – 332 98 – 236 84 – 267 106 – 214 130 – 323 119 – 236  84 – 328 95 – 324  
No. of patients (%) 67 (98.53%) 28 (41.18%) 54 (91.53%) 32 (54.24%) 32 (100.00%) 13 (40.63%)  36 (94.74%) 17 (44.74%)  
             
LDL cholesterol (mg/dL) 
Mean (SD)  140.93 (34.98) 85.18 (22.75) < 0.001 106.05 (36.91) 87.71 (25.54) 0.01 141.38 (39.04) 100.43 (43.03) < 0.001 113.37 (43.96) 89.85 (41.21) 0.01 
Range  62 – 283 11 – 326 35 - 185 10 – 406 81 - 236 14 - 262  43 - 223 14 – 327  
No. of patients (%) 68 (100.00%) 45 (66.18%) 59 (100.00%) 45 (76.27%) 32 (100.00%) 23 (71.88%)  38 (100.00%) 27 (71.05%)  
Duration, days (mean (SD)  133.17 (93.55)   136.60 (99.00)   91.45 (70.68)   112.92 (90.34)  
             
HDL cholesterol (mg/dL) 
Mean (SD)  43.29 (14.18) 48.06 (14.31) 0.023 39.14 (12.90) 46.94 (12.58) 0.002 37.09 (11.72) 45.07 (13.11) 0.001 36.95 (11.67) 46.63 (16.91) 0.008 
Range 17 - 88 24 – 81 10 – 82 32 – 81 16 – 63 33 – 85  20 – 83 26 – 95  
No. of patients (%) 68 (100.00%) 34 (50.00%) 56 (94.92%) 35 (59.32%) 32 (100.00%) 15 (46.88%)  37 (97.37%) 19 (50%)  
             
Triglyceride (mg/dL) 
Mean (SD)  133.63 (72.09) 104.23 (37.22) 0.194 117.61 (71.03) 120.24 (59.29) 0.985 172.38 (84.78) 149.60 (76.22) 0.181 130.11 (43.43) 157.32 (95.21) 0.236 
Range 55 – 475 42 – 198 40 – 397 37 – 300 65 – 336 60 – 336  54 – 240 52 – 456  
No. of patients (%) 68 (100.00%) 31 (45.59%) 57 (96.61%) 37 (62.71%) 32 (100%) 15 (46.88%)  37 (97.37%) 19 (50%)  
             
ALT (IU/L) 
Mean (SD)  22.52 (18.89) 27.73 (18.88) 0.366 25.26 (17.01) 24.86 (15.18) 0.747 27.08 (14.49) 30.32 (24.30) 0.456 28.47 (14.88) 24.26 (10.66) 0.277 
Range 9 – 103 10 – 103 8 – 82 10 – 81 6 – 61 10 – 119  9 – 66 10 – 56  
No. of patients (%) 23 (33.82%) 33 (48.53%) 27 (45.76%) 37 (62.71%) 12 (37.50%) 19 (59.38%)  17 (44.74%) 19 (50%)  
             
AST (IU/L) 
Mean (SD)  27.45 (12.23) 26 (8.30)   0.110 30.56 (17.01) 28.03 (9.45) 0.804 25.92 (5.18%) 25.37 (8.76) 0.834 31.59 (11.12) 23.37 (7.48) 0.014 
Range 14 - 56 11 – 56 12 – 86 13 – 57 18 – 34 13 – 48  15 – 54 13 – 39  
No. of patients (%) 22 (32.35%) 32 (47.06%) 27 (45.76%) 35 (59.32%) 12 (37.50%) 19 (59.38%)  17 (44.74%) 19 (50.00%)  
             
Creatine kinase (IU/L) 
Mean (SD)  88.33 (8.96) 117 (68.66) - 80.25 (45.04) 134.27 (54.12) 0.295 85.00 (5.18) 99.50 (45.74) - 77.00 (9.90) 95 (58.62) - 
Range 78 – 94 43 – 240 29 - 126 21 – 208 49 – 121 34 – 140  70 – 84 35 – 165  
No. of patients (%) 3 (4.41%) 6 (8.82%) 4 (6.77%) 11 (18.64%) 2 (6.25%) 4 (12.5%)  2 (5.26%) 5 (13.16%)  
             
Fasting blood sugar (mg/dL) 
Mean (SD)  97.90 (15.26) 101.26 (15.14) 0.268 102.33 (25.85) 101.21 (15.28) 0.139 160.38 (66.69) 152.48 (56.92) 0.71 136.97 (47.50) 128.35 (40.41) 0.576 
Range 65 – 137 78 – 145 71 – 200 74 – 151 60 – 375 86 – 322  70 – 261 46 – 228  
No. of patients (%) 67 (98.53%) 39 (57.35%) 58 (98.31%) 33 (56.93%) 32 (100.00%) 23 (71.88%)  38 (100.00%) 31 (81.58%)  
             
HbA1c (%) 
Mean (SD)  6.28 (1.63) 6.4 (0.96) - 5.98 (0.68) 5.7 (0.28) - 9.15 (2.51) 8.85 (3.33) 0.779 7.95 (2.10) 6.9 (0.83) 0.427 
Range 5.10 – 13.00 5.8 – 8 5 – 6.8 5.5 – 5.9 4.9 – 13.4 5.5 – 13.7  6 – 13 6 – 8.2  
No. of patients (%) 21 (30.88%) 5 (7.35%) 10 (16.95%) 2 (3.39%) 22 (68.75%) 6 (18.75%)  21 (55.26%) 5 (13.16%)  
* Paired t test comparing measure at admission with the one at follow-up, with a significance level of 0.05  
Note: Groups of patients: group A = patients with no diabetes mellitus (DM) and no statin use before admission; group B = patients with no DM and with statin use before admission; group C = patients with DM and no statin use 
before admission; group D = patients with DM and statin use before admission.  
Abbreviation: LDL = low density lipoprotein; HDL = high density lipoprotein; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HbA1C = glycosylated hemoglobin.  
 
 
There was no myalgia or rhabdomyolysis reported in this 
study (Table 4). Simvastatin was the most prescribed lipid 
lowering drug in patients with ischemic stroke and 
hyperlipidemia (176 cases, 89.34%), followed by atorvastatin 
(14 cases, 7.11%) (Table 4). Mean doses of simvastatin in 
each group were comparable, 20.49, 18.60, 20.0, and 21.71 
mg in group A, B, C and D, respectively. 
 
Discussions 
According to the recommendation for lipid management 
from National Cholesterol Education Panel or NCEP III 
(Class I recommendations), the target goal of cholesterol 
lowering for those patients with CHD or symptomatic 
atherosclerotic disease is LDL-C level < 100 mg/dL; while 
the LDL-C level < 70 mg/dL is recommended for a very high   
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Table 3 LDL-C goal achievements  
Group 
LDL-C < 100 mg/dL LDL-C  100 mg/dL 
Number of 
patients (%) 
Mean LDL-C 
(SD) 
Range Number of 
patients (%) 
Mean LDL-C 
(SD) 
Range 
A (N = 45 ) 37 
(82.22%) 
77.76 
(14.38) 
42 - 99  8 
(17.77%) 
119.50 
(23.48) 
100 - 168 
       
B (N = 45 ) 31 
(68.89%) 
75.00 
(15.92) 
38 - 98 14 
(31.11%) 
115.86 
(19.60) 
100 - 152 
       
Group 
LDL < 70 mg/dL LDL  70 mg/dL 
Number of 
patients (%) 
Mean LDL-C 
(SD) Range 
Number of 
patients (%) 
Mean LDL-C 
(SD) Range 
C (N = 23 ) 5 
(21.74%) 
55.60 
(11.39) 
41 – 67 18 
(78.26%) 
112.89 
(40.13) 
70 - 242 
       
D (N = 27 ) 10 
(37.04%) 
57.10 
(9.34) 
39 - 68 17 
(62.96%) 
109.12 
(40.56) 
70 - 206 
Note: Groups of patients: group A = patients with no diabetes mellitus (DM) and no statin use before admission; 
group B = patients with no DM and with statin use before admission; group C = patients with DM and no statin 
use before admission; group D = patients with DM and statin use before admission.  
Abbreviation: LDL-C = low density lipoprotein cholesterol.  
 
 
Table 4 Type of statins and adverse drug reactions 
classified by study groups.  
 Group 
A (N = 68) B (N = 59) C (N = 32) D (N = 38) 
Adverse drug reactions     
Myalgia 
Rhadomyolysis 
0 
0 
0 
0 
0 
0 
0 
0 
Statins      
Simvastatin 
Atrovastatin 
Rosuvastatin 
61 (89.7%) 
6 (8.80%) 
1 (1.50%) 
50 (84.75%) 
5 (8.47%) 
4 (6.78%) 
30 (93.80%) 
1 (3.10%) 
1 (3.10%) 
35 (92.10%) 
2 (5.30%) 
1 (2.60%) 
Statin plus fibrate     
Gemfibrozil 0 1 (1.69%) 1 (3.13%) 0 
Note: Groups of patients: group A = patients with no diabetes mellitus (DM) and no statin use before admission; 
group B = patients with no DM and with statin use before admission; group C = patients with DM and no statin 
use before admission; group D = patients with DM and statin use before admission.  
 
risk person with multiple risk factors.7 This present study 
classified 197 patients admitted at a stroke unit according to 
statin drug use history and the underlying disease of 
diabetes mellitus. After hospital discharge from stroke unit, 
the LDL-C achieved rate according to LDL-C goal 
accomplishment of < 100 mg/dL were 82.22% among 
patients patient without DM and no statin use before 
admission, and 68.89% among those without DM and with 
statin use before admission. In a previous study of patients 
with ischemic stroke or TIA admitted in the stroke service of 
a university teaching hospital, it was found that percent of 
individuals with LDL-C < 100 mg/dL at admission was 46% 
and then increased to 83% at 3 months after hospitalization 
but data of lipid lowering drug history was not disclosed.8 L-
TAP 2 study which was a survey performed in more than 
10,000 patients in 9 countries, the success rate for LDL-C 
goal achievement (LDL-C < 100 mg/dL) was 73% overall, 
ranging from 47% to 84% across countries.9 A high rate of 
LDL-C goal achievement in group A (82.22%) observed in 
our study may be due to an initiation of statin treatment for 
patients with ischemic stroke and TIA during their 
hospitalization. These patients might also had a high rate of 
adherence to statin therapy after hospital discharge. Such 
adherence could probably associate with a substantial 
improvement in the proportions of patients achieving target 
national guideline LDL-C goals 3 months after 
hospitalization.10  
In patient without DM and had used statin (group B), 
both of the control rate of LDL-C according to LDL-C goal 
accomplishment and mean LDL-C at admission were lower 
than patients with no diabetes and no statin use. Previous 
study has shown that among patients in whom treatment 
with secondary preventive drugs was prescribed at 
discharge, the proportion on persistent medication during the 
first 4 months after discharge varied from 95.5% for 
antihypertensive drugs, 91.7% for statin drugs to 89.1% for 
warfarin. At 2 years, the rates had decreased to 74.2% for 
antihypertensive drugs, 56.1% for statin drugs and to 45.0% 
for warfarin. 11 Although this study did not record the history 
of statin use durations and adherence in sample, 
nonadherence after stroke was a major clinical problem in 
available evidence.11 
In the study of Thailand Diabetes Registry Project 
entitled “Current Status of Dyslipidemia in Thai Diabetic 
Patients”12, the achievement rate of the LDL-C target (< 70 
mg/dL) in diabetic patients with history of cardiovascular 
disease was only 11.1%. Half of the patients (55%) were 
taking lipid–lowering medication; however, another one-third 
(30%) did not take any lipid-lowering medication even though 
they should.12 According to American Diabetes Association 
recommendation, the LDL-C level < 70 mg/dl in type 2 DM 
with overt cardiovascular disease, about 28% of patients met 
target in Reality–Asia study.13 Among 7,427 coronary artery 
disease (CAD) patients, 43% achieved an LDL-C goal (< 70 
mg/dL), and 37% of those taking statin monotherapy14. In 
our study, diabetic patients with history of ischemic stroke or 
TIA who taking statin drugs attained the target LDL-C for 
21.74% in those not taking statin and 37.04% in those taking 
statin before admission. A relatively low success rate may be 
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due to the use of statin with low potency (simvastatin) in the 
majority of our patients (176 cases, 89.34%); while in 
previous study13, only 37% received statin with low potency.   
Recent studies suggest that a more aggressive target for 
lipid lowering may have added benefits, LDL-C change 
showed that patients with > 50% LDL-C reduction had a 
31% reduction in stroke risk (hazard ratio, 0.69, 95% CI, 
0.55 to 0.87, P = 0.0016), a 33% reduction in ischemic 
stroke (P = 0.0018), no statistically significant increase in 
hemorrhagic stroke (P = 0.8864), and a 37% reduction in 
major coronary events (P = 0.0323).15 In addition, every 1-
mmole (39 mg/dL) decrease in LDL-C was associated with a 
17% reduction in fatal and nonfatal stroke.11 In our study, a 
more potent statin could have lead to a larger decrease in 
LDL and consequently a higher rate of LDL-goal 
achievement. Unfortunately, health care system of Thailand 
has the limitation of drug access, especially in patient with 
the universal coverage policy where high potency statins 
were not allowed in the majority of patients in this study. 
With the approval of atrovastatin in a dose of 40 mg in the 
essential drug list of Thailand in 2012, a higher rate of LDL-
C goal achievement could be seen in the future. However, 
not only the use of high potency drug, other measures 
including education should be considered influential for 
achieving treatment goal.  
In terms of adverse drug reaction, myalgia and 
rhabdomyolysis were not found in this study. Nevertheless, 
the means of ALT were not more than 3 times of upper 
normal limit at admission and follow-up. The changes in AST 
and ALT levels were not clinically or statistically significant. 
In clinical practice, when an increase in ALT levels was 
observed, physicians discontinue or reduce statin dosage. 
Another reason for lack of reported adverse effects was the 
possible incomplete information in the medical charts. In a 
previous study, myalgia and rhabdomyolysis were detected 
in 3.2% and 0.5% of patients, respectively.16 A high 
occurrence of rhabdomyolysis was due to the concurrent use 
of high dosage of gemfibrozil (1,200 mg).16 Nevertheless, the 
estimation of rhabdomyolysis from randomized control trial of 
statin is similar to the corresponding estimate from the 
cohort studies of 3.4 per 100,000 person-year.16 The study of 
the effectiveness of additional reductions in cholesterol and 
homocysteine found that myopathy rate of was 0.9% 
associating with a high dose of simvastatin (80 mg/day) and 
0.05% with a low dose (20 mg/day). Likewise, 
rhabdomyolysis rate in high dose of simvastatin (80 mg/day) 
was 0.12% and not found in low dose (20 mg/day).17 In this 
study, the combination of simvastatin 20 mg and gemfibrozil 
600 mg per day was prescribed in 2 cases, but adverse drug 
reaction was not found.  
The absence of adverse drug reactions, myalgia or 
rhabdomyolysis, were seen due to the low dosage of statin 
drugs of which simvastatin and atrovastatin doses were not 
more than 40 mg per day and rosuvastatin was not more 
than 10 mg per day. Since data of adverse drug reactions 
were reviewed from medical chart, the estimate of adverse 
events may be underreported.  
This study has few limitations. Since we did not exclude 
some patients who reached the goal of LDL-C level at 
admission, LDL-C goal achievement could be overestimated. 
Secondly, retrospective medical chart review in this study 
could lead to an underestimate of adverse drug reactions of 
statins. Findings from this study could help inform for 
multidisciplinary healthcare providers the success rate of 
LDL-goal achievement. A more aggressive hyperlipidemia 
therapy and an intensive patient education program should 
be encouraged. 
 
Conclusion   
This study determined the goal achievement of LDL-C in 
patients with ischemic stroke and hyperlipidemia at Prasat 
Neurological Institute. LDL-C goal accomplishment rates 
(LDL-C < 100 mg/dL) among patients with no diabetes were 
82.22% and 68.89% for those without and with statin use 
before admission respectively. For patients with diabetes, 
LDL-C goal accomplishment rates (LDL < 70 mg/dL) of 
21.74% and 37.04% were found in patients without and with 
statin use before admission respectively. Myalgia or 
rhabdomyolysis was not found in this study. 
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